Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C
Status and phase
Conditions
Treatments
Details and patient eligibility
About
This study is being conducted in treatment-naive patients (no previous hepatitis C treatment) to evaluate the safety of valopicitabine (NM283) alone and together with pegylated interferon, a drug approved by the Food and Drug Administration for the treatment of hepatitis C infection. This study is also evaluating the ability of valopicitabine to decrease the amount of hepatitis C virus in the body. The results for patients taking valopicitabine alone will be compared with the results for patients taking valopicitabine together with pegylated interferon.
Sex
Ages
Volunteers
Inclusion criteria
- Documented clinical history compatible with genotype-1, chronic hepatitis C infection
- Treatment-naive (patient has received no previous therapy for hepatitis C viral infection)
Other protocol-defined inclusion criteria may apply.
Exclusion criteria
- Patient is pregnant
- Patient is co-infected with hepatitis B or HIV
Other protocol-defined exclusion criteria may apply.
Trial design
Primary purpose
Allocation
Interventional model
Masking
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal